BICX · BioCorRx Inc.
Substantial doubt about the company's ability to continue as a going concern.
“As of June 30, 2026, the Company had cash of $21,237 and working capital deficit of $8,231,326. During the six months ended June 30, 2026, the Company used net cash in operating activities of $873,260. The Company has incurred net losses since inception. These conditions raise substantial doubt about the Company's ability to continue as a going concern for the next twelve-month period since the date of the financial statements were issued.”View the 10-Q filed Aug 14, 2026
2 customers — 100% of revenue (three months ended June 30, 2026)
“The Company's revenues earned from sale of products and services for the three months ended June 30, 2026 included 100% from two customers of the Company's total revenues.”
2 customers — 99% of revenue (three months ended June 30, 2025)
“The Company's revenues earned from sale of products and services for the three months ended June 30, 2025 included 99% from two customers of the Company's total revenues.”
Private capital raises reported to the SEC on Form D under Regulation D, showing the offering size, amount sold, minimum investment and number of investors. Public operating companies rarely raise capital this way, so this page is often empty.
No Exempt Offerings
No Form D exempt-offering notices are available for this stock yet.